CD274 Overexpression

CI-VAR-00003238Explore in graph →CIViC 4522

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma5
MET Exon 14 Skipping Mutation AND CD274 Overexpression	Pembrolizumab	Predictive	C	Supports Resistance	3	submitted	EID11396 A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC) PMID 30600919 · Baba et al., 2019 · Open in CIViC	civic
MET Exon 14 Skipping Mutation AND CD274 Overexpression	Carboplatin + PemetrexedCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID11397 A 71-year old woman (non-smoker) was diagnosed with poorly differentiated lung adenocarcinoma following immunohistochemistry of tumor cells and biopsy staining. High PD-L1 expression was also confirme… (full text at CIViC) PMID 30600919 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Non-Small Cell Carcinoma1
MET Exon 14 Skipping Mutation AND CD274 Overexpression	Pembrolizumab	Predictive	B	Does Not Support Sensitivity Response	2	submitted	EID11419 Twenty-four patients with MET exon 14 skipping mutation and PD-L1 expression >50% were included in this retrospective study. Median overall survival of these patients was 12.1 months (CI: 9.1 - NR) an… (full text at CIViC) PMID 36210290 · Guisier et al., 2022 · Open in CIViC	civic

Lung Sarcomatoid Carcinoma2
MET Exon 14 Skipping Mutation AND CD274 Overexpression	Carboplatin/Pemetrexed Regimen + PembrolizumabCombination	Predictive	C	Supports Sensitivity Response	2	submitted	EID11457 A 65-year old male (non-smoker) presented with advanced sarcomatoid non-small-cell lung cancer harboring a MET exon 14 skipping mutation with elevated PDL1 levels (tumor proportion score of 80%). Afte… (full text at CIViC) PMID 35871685 · Gonugunta et al., 2022 · Open in CIViC	civic
MET Exon 14 Skipping Mutation AND CD274 Overexpression	Nivolumab	Predictive	C	Supports Sensitivity Response	3	submitted	EID11414 A 58-year old male (non-smoker/non-drinker) was diagnosed with metastatic adenocarcinoma with sarcomatoid components. A tissue sample revealed a MET exon 14 skipping mutation and the patient was treat… (full text at CIViC) PMID 35110965 · Gu et al., 2022 · Open in CIViC	civic